Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed/Refractory AML: early-phase trial registry
A small indexed set (3 trials) with no open enrollment listed right now.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · none currently recruiting · #5,209 of 28,707 conditions by registered trial count
Relapsed/Refractory AML: 3 US clinical trials tracked, none currently recruiting.
Relapsed/Refractory AML is the subject of 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Faron Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition relapsedrefractory-aml
OPEN 0 | RECR 0% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Relapsed/Refractory AML has no open enrollment in this registry pull (3 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed/Refractory AML on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed/Refractory AML is recruiting below its size-band peers.
0 of 3 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
3 total, page 1 of 1
A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Faron Pharmaceuticals
NCT05428969
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
Nkarta
NCT04623944
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics
NCT06846606
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed/Refractory AML records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed/Refractory AML trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed/Refractory AML page
3 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Relapsed/Refractory AML trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Faron Pharmaceuticals sponsors the most Relapsed/Refractory AML trials on record, review their full trial history before evaluating a specific study. See Faron Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed/Refractory AML condition card totals 3 registered trials; most-linked intervention Bexmarilimab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.